Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GLX Analytix
Likely Aarhus (rooted in Aarhus University), possibly Copenhagen (not definitively specified), Denmark
- Ownership
- Private
- Development stage
- Other
01
Overview
GLX Analytix has developed the GLX Signature blood test assay using proprietary immunoassay and machine learning to detect patterns of endothelial glycocalyx degradation, providing early diagnosis and monitoring for neurodegenerative and neuropsychiatric diseases; clinical validation and commercialization are currently ongoing[2][3].
- Therapeutic areas
- ImmunologyNeurologyPsychiatry
- Modalities
- Diagnostic assayBiomarkerArtificial intelligence (AI)-integrated diagnostics
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
Labcorp Venture FundAlzheimer’s Drug Discovery Foundation (ADDF)EIFODigitalDx Ventures
Beyond the preview
Go deeper on GLX Analytix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLX Analytix.